These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29060940)

  • 1. Everyday Memory in Patients with Alzheimer's Disease: Fragmentary and Distorted.
    Sejunaite K; Lanza C; Riepe MW
    J Alzheimers Dis; 2017; 60(4):1489-1498. PubMed ID: 29060940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
    Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
    J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everyday false memories in older persons with depressive disorder.
    Sejunaite K; Lanza C; Riepe MW
    Psychiatry Res; 2018 Mar; 261():456-463. PubMed ID: 29407717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
    Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
    J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder.
    Borroni B; Premi E; Agosti C; Alberici A; Cerini C; Archetti S; Lanari A; Paghera B; Lucchini S; Caimi L; Padovani A
    J Neurol Neurosurg Psychiatry; 2011 Aug; 82(8):834-8. PubMed ID: 21345847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.